Article
In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice.
Molecules (Basel, Switzerland) - 28 Aug 2022
Bhat Zahid Rafiq, Kumar Manvendra, Sharma Nisha, Yadav Umesh Prasad, Singh Tashvinder, Joshi Gaurav, Pujala Brahmam, Raja Mohd, Chatterjee Joydeep, Tikoo Kulbhushan, Singh Sandeep, Kumar Raj
Abstract excerpt
Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a non-covalent imidazo[1,2-a]quinoxaline-based EGFR inhibitor (6b), which showed promising inhibitory activity against the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.